|
According to existing reports, Myeloproliferative neoplasms(MPNs), including PMF, PV, and ET, are a group of diseases of the bone marrow in which excess cells are produced, and characterized by hepatosplenomegaly, anemia, leukocytosis, thrombocytosis, constitutional symptoms, and cachexia clinically. Erythropoietin, androgens, and thalidomide all have been used in the treatment of MPNs. However, the efficacy of drug therapy is not as good as expected: neither curative nor adequately palliative. Some small molecule kinase inhibitors of JAK (eg, INCB018424 and CP-690550) have been investigated to show the therapeutic potential, since a JAK2 mutation (JAK2V617F) has been widely observed in most patients with MF, PV, or ET. And in this post, I will mainly talk about Ruxolitinib (INCB018424), an ATP competitive JAK1 and JAK2 inhibitor. At present, INCB018424 has undergone phase 1, 2, and 3 trials, and the maximum tolerated dose (MTD) was about 25 mg twice daily and 100 mg once daily, though leading to Thrombocytopenia. In the paper published recently, Tefferi and Pardanani reported the new findings on the subject. In order to explore the long-term ruxolitinib treatment outcome, they focus on the treatment discontinuation of ruxolitinib in MF. The existing data show that a high treatment discontinuation rate (92%) is observed after a median time of 9.2 months, and probably caused by drug-associated adverse effects. Also rapid changes in inflammatory cytokine activity may contribute to the underlying mechanism for “ruxolitinib discontinuation syndrome”[1]. In summary, serious adverse effects will be observed in ruxolitinib treatment discontinuation in patients with myelofibrosis. Thus it is suggested that patients should also be alerted about the need for gradual tapering of the drug under close physician supervision. We has established long-term and stable relationships with more than 10,000 customers from pharmaceutical and biotech companies, universities and research institutions. We have high quality inhibitors like PF-2341066, Sunitinib, Temsirolimus, Vorinostat, Abiraterone & more. We have headquarters in both United States and Europe, and also has 38 distributors worldwide. We provide overnight delivery in North America and Europe. Reference [1]. Mayo Clin Proc. 2011;86(12):1188-1191? Related Post Clinical efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
Related Articles -
PF-2341066, Sunitinib, Vorinostat,
|
